NEXALIN TECHNOLOGY INC. - COMMON STOCK

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

01 Nov 2024 09:34:54 By Nasdaq GlobeNewswire

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

28 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

22 Oct 2024 13:15:00 By Nasdaq GlobeNewswire

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

17 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

14 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

18 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Closing of $5.2 Million Public Offering

01 Jul 2024 13:45:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

27 Jun 2024 20:15:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

26 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

20 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

13 Jun 2024 14:00:00 By Nasdaq GlobeNewswire

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

04 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

03 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

22 May 2024 07:30:00 By Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

25 Apr 2024 09:44:22 By Nasdaq GlobeNewswire

Nexalin Technology CEO Provides Letter to Shareholders

10 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

09 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

04 Apr 2024 12:00:00 By Nasdaq GlobeNewswire